Method and formulations for use in treating benign gynecological disorders
First Claim
Patent Images
1. A composition comprising:
- a slow-release formulation of a gonadotropin hormone releasing hormone composition which maintains serum level of said gonadotropin hormone releasing hormone composition in a female mammal at a level effective to suppress ovarian estrogen and progesterone production over a period of time, wherein said gonadotropin hormone release hormone composition is administered at a rate between about 0.0001 and 10 mg/kg of body weight per day; and
a slow-release formulation of an estrogenic composition which maintains serum level of said estrogenic composition over said period of time at a level effective to prevent symptoms and signs of estrogen deficiency, wherein said serum level of said estrogenic composition is equivalent to serum estrodiol levels in the range of about 25 to about 140 pg/ml.
2 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods which are effective to treat benign gynecological disorders for extended periods of time in women in who the risk of endometrial stimulation is minimized or absent are described, wherein an effective amount of a gonadotropin hormone releasing hormone composition and an effective amount of an estrogenic composition are provided over a period of time, optionally with addition of an androgenic composition.
143 Citations
21 Claims
-
1. A composition comprising:
-
a slow-release formulation of a gonadotropin hormone releasing hormone composition which maintains serum level of said gonadotropin hormone releasing hormone composition in a female mammal at a level effective to suppress ovarian estrogen and progesterone production over a period of time, wherein said gonadotropin hormone release hormone composition is administered at a rate between about 0.0001 and 10 mg/kg of body weight per day; and a slow-release formulation of an estrogenic composition which maintains serum level of said estrogenic composition over said period of time at a level effective to prevent symptoms and signs of estrogen deficiency, wherein said serum level of said estrogenic composition is equivalent to serum estrodiol levels in the range of about 25 to about 140 pg/ml. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 18, 19)
-
-
10. A method for treating benign gynecological disorders in a patient in whom risk of endometrial stimulation by estrogenic compositions is minimized or absent, comprising:
-
administering a gonadotropin hormone releasing hormone composition for a first period of time in an amount effective to maintain serum level of said gonadotropin hormone releasing hormone composition at a level effective to suppress ovarian estrogen and progesterone production, wherein said gonadotropin hormone releasing hormone composition is administered at a rate between about 0.0001 and 10 mg/kg of body weight per day; and simultaneously administering an estrogenic composition in an amount effective to maintain serum level of said estrogenic composition over said first period of time at a level effective to prevent signs and symptoms of estrogen deficiency, wherein said serum level of said estrogenic composition is equivalent to serum estradiol levels in the range of about 25 to about 140 pg/ml. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 20, 21)
-
Specification